StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) stock

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30
$0.80−0.01 (-0.86%)

Close on Nov 16, 2026Market cap $103.34MP/E –Yield –

Organogenesis ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Organogenesis's ebitda for the twelve months ending Jun 30, 2026 was -$19.93M. For fiscal 2025 it was $59.97M, up 386.0% from the year before.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.97M+386.0%
FY2024Dec 31, 2024$12.34M-46.3%
FY2023Dec 31, 2023$22.97M-18.4%
FY2022Dec 31, 2022$28.15M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$47.32M–
Q1 FY2026Mar 31, 2026-$64.72M–
Q4 FY2025Dec 31, 2025$67.36M+386.9%
Q3 FY2025Sep 30, 2025$24.76M+152.3%
Q2 FY2025Jun 30, 2025-$8.84M–
Q1 FY2025Mar 31, 2025-$23.30M–
Q4 FY2024Dec 31, 2024$13.83M+707.6%
Q3 FY2024Sep 30, 2024$9.81M-7.4%
Q2 FY2024Jun 30, 2024-$10.53M-187.9%
Q1 FY2024Mar 31, 2024-$780.00K–
Q4 FY2023Dec 31, 2023$1.71M–
Q3 FY2023Sep 30, 2023$10.59M–
Q2 FY2023Jun 30, 2023$11.97M–

More Organogenesis figures

See a number that looks wrong?